Conclusions
depressive illness, TRD, AD, AD +
Significant improvement in HRQoL, health status, and functional outcomes was observed among patients with TRD treated with ESK + AD compared with those treated with AD + PBO within 4 weeks of initiating treatment. ESK in combination with an oral AD appears to offer meaningful benefit as a treatment option for patients with TRD who generally have substantial HRQoL and functioning limitations as a result of their depressive illness.